Clinical Trials & Results
Search or filter the listing below to find a trial or results of a completed trial.
Showing 13 of 13 Results
All Results
No results found
Please change the filter settings to find the product(s) you are looking for. You can also use the search function to look up a product.
Clear Filters
Efficacy, Safety, and Tolerability of Laquinimod in Relapsing Remitting Multiple Sclerosis
- Condition(s):
- Multiple Sclerosis
- Status:
- Completed
- Requirements:
- 18 Years to 55 Years
- Interventions:
- Drug: Laquinimod | Drug: Placebo
Evaluation of Two Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis
- Condition(s):
- Multiple Sclerosis
- Status:
- Completed
- Requirements:
- 18 Years and older
- Interventions:
- Drug: Glatiramer Acetate 20 mg/0.5 mL | Drug: Glatiramer acetate 20 mg/0.5 mL
Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis
- Condition(s):
- Multiple Sclerosis
- Status:
- Completed
- Requirements:
- 18 Years to 45 Years
- Interventions:
- Drug: Glatiramer Acetate (DB)|Drug: Placebo | Drug: Glatiramer Acetate (OL)
Impact of Multiple NAb Tests Compared to Usual Care of MS Patients on High-dose IFN Therapy
- Condition(s):
- Multiple Sclerosis
- Status:
- Completed
- Requirements:
- 18 Years and older
- Interventions:
- Procedure: NAbs testing
Laquinimod in Participants With Relapsing-Remitting Multiple Sclerosis with Avonex® Reference Arm
- Condition(s):
- Multiple Sclerosis
- Status:
- Completed
- Requirements:
- 18 Years to 55 Years
- Interventions:
- Drug: laquinimod | Drug: placebo | Drug: Interferon ־²-1a (Avonexֲ®)
Safety and Efficacy of Laquinimod Versus Placebo for Relapsing Remitting Multiple Sclerosis
- Condition(s):
- Multiple Sclerosis
- Status:
- Completed
- Requirements:
- 18 Years to 55 Years
- Interventions:
- Drug: Laquinimod | Other: Placebo
Study Comparing Shared Solutions® Plus MS Center Support Versus Shared Solutions® Alone
- Condition(s):
- Multiple Sclerosis
- Status:
- Completed
- Requirements:
- 18 Years and older
- Interventions:
- Procedure: Shared Solutionsֲ® plus MS Center v. Shared Solutionsֲ®
Study to Assess Satisfaction in Patients Treated With Copaxone®
- Condition(s):
- Multiple Sclerosis
- Status:
- Completed
- Requirements:
- 18 Years and older
- Interventions:
- Drug: Copaxoneֲ®
Study to Evaluate an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.
- Condition(s):
- Multiple Sclerosis
- Status:
- Completed
- Requirements:
- 18 Years and older
- Interventions:
- Drug: glatiramer acetate injection with oral cetirizine hydrochloride | Drug: glatiramer acetate with placebo
Study to Evaluate Reactions of Using Alcohol Wipes Prior to Daily Injections of Copaxone®.
- Condition(s):
- Multiple Sclerosis
- Status:
- Completed
- Requirements:
- 18 Years and older
- Interventions:
- Procedure: Alcohol Wipes vs. No Alcohol Wipes
Study to Evaluate Readiness to Self-inject on Adherence and Compliance to Copaxone® Therapy
- Condition(s):
- Multiple Sclerosis
- Status:
- Completed
- Requirements:
- 18 Years and older
Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone®
- Condition(s):
- Multiple Sclerosis
- Status:
- Completed
- Requirements:
- 18 Years to 55 Years
- Interventions:
- Drug: glatiramer acetate | Procedure: Warm compress prior to injection of glatiramer acetate
Therapy Optimization in Multiple Sclerosis
- Condition(s):
- Multiple Sclerosis
- Status:
- Completed
- Requirements:
- 18 Years and older
- Interventions:
- Drug: Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b
